Plexiform neurofibroma - Pipeline Insight, 2024

This “Plexiform neurofibroma - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Plexiform neurofibroma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Plexiform neurofibroma Understanding

Plexiform neurofibroma: Overview

Plexiform neurofibromas are a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Although these tumors tend to grow slowly, they may grow to an enormous size and can cause serious disfigurement, brain dysfunction or impingement on other organs. They may also cause pain. Until recently, the only known effective treatment for plexiform neurofibromas has been surgery. Approximately 75% of patients who undergo a complete removal of the tumor without causing significant neurologic impairment or dysfunction are cured. Although diagnosis of these lesions is usually possible by examination of the child, the full extent of the lesion is best seen by MRI scan. MRI scans may show these lesions to be much more extensive than previously thought. For those patients with tumors around the spine, the lesions may be extremely extensive.

Plexiform neurofibroma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Plexiform neurofibroma pipeline landscape is provided which includes the disease overview and Plexiform neurofibroma treatment guidelines. The assessment part of the report embraces, in depth Plexiform neurofibroma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Plexiform neurofibroma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Plexiform neurofibroma R&D. The therapies under development are focused on novel approaches to treat/improve Plexiform neurofibroma.

Plexiform neurofibroma Emerging Drugs Chapters

This segment of the Plexiform neurofibroma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Plexiform neurofibroma Emerging Drugs

Mirdametinib: Spring Works Therapeutics Mirdametinib is an oral, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1-associated plexiform neurofibromas, or NF1-PN, and as a combination therapy for the treatment biomarker defined metastatic cancers with mutations in the MAPK pathway, such as in RAS and RAF. Mirdametinib is designed to inhibit MEK1 and MEK2. MEK proteins occupy a pivotal position in the MAPK pathway, which is a key signaling network that regulates cell growth and survival, and that plays a central role in multiple oncology and rare diseaseindications.

Binimetinib: Array Bio Pharma Binimetinib is an orally bioavailable, small-molecule, allosteric inhibitor of MAP kinase 1 and 2 (MEK1/2), developed by Array Biopharma (a subsidiary of Pfizer). Currently, it is in Phase II stage of clinical trial evaluation to treat NF1 PlexiformNeurofibromas.

Plexiform neurofibroma: Therapeutic Assessment

This segment of the report provides insights about the different Plexiform neurofibroma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Plexiform neurofibroma

There are approx. 5+ key companies which are developing the therapies for Plexiform neurofibroma. The companies which have their Plexiform neurofibroma drug candidates in the most advanced stage, i.e. phase II include, Spring WorksTherapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Plexiform neurofibroma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Plexiform neurofibroma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Plexiform neurofibroma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plexiform neurofibroma drugs.

Plexiform neurofibroma Report Insights

• Plexiform neurofibroma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Plexiform neurofibroma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Plexiform neurofibroma drugs?
• How many Plexiform neurofibroma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Plexiform neurofibroma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Plexiform neurofibroma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Plexiform neurofibroma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Spring WorksTherapeutics
• Array BioPharma
• Novartis
• Shanghai Fosun Pharmaceutical Development Co, Ltd.
• Ashvattha Therapeutics

Key Products

• Mirdametinib
• Binimetinib
• Everolimus
• FCN-159
• Nivolumab

Research programme: hydroxyl dendrimer therapeutics


This product will be delivered within 1-3 business days.